HOUSTON, May 16, 2024
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
("Moleculin" or the "Company"), a clinical stage pharmaceutical
company with a broad portfolio of drug candidates targeting
hard-to-treat tumors and viruses, today announced its abstract has
been accepted for poster presentation at the EHA2024 Hybrid
Congress being held June 13-16, 2024
in Madrid, Spain and
virtually.
Details for the poster presentation are as follows:
Abstract: P537
Session: Acute myeloid leukemia – Clinical
Title: LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH
CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA
(AML) REFACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY
(MB-106 STUDY)
Presenting Author: Wolfram C. M. Dempke, MD, PhD, MBA, European
Chief Medical Officer of Moleculin
For more information about the EHA2024 Hybrid Congress, visit
the event website.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms and to eliminate the
cardiotoxicity common with currently prescribed anthracyclines.
Annamycin is currently in development for the treatment of relapsed
or refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases. All interim and preliminary data discussed
above are subject to change.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-european-hematology-association-eha-2024-hybrid-congress-302146725.html
SOURCE Moleculin Biotech, Inc.